SURAKSHA326.20

Suraksha Diagnostic Limited

· Pharma & Health
₹ CrorePeersKRSNAAHEALTHXNEPHROPLUS3BBLACKBIOMcap ₹1,699 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)99.5281.4981.49
Receivable Days (DSO)20.0026.7626.76
Payable Days (DPO)168.70208.76202.35
Cash Conversion Cycle (days)-49.18-100.51-94.10
Working Capital Turnover56.82106.04110.47
Asset Turnover0.760.690.69
Cash Conversion (CFO/Net Income)2.052.612.61
CFO/EBITDA0.780.860.86
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.